"Heterozygote" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An individual having different alleles at one or more loci regarding a specific character.
| Descriptor ID |
D006579
|
| MeSH Number(s) |
G05.380.383
|
| Concept/Terms |
Genetic Carriers- Genetic Carriers
- Carrier, Genetic
- Genetic Carrier
- Carriers, Genetic
|
Below are MeSH descriptors whose meaning is more general than "Heterozygote".
Below are MeSH descriptors whose meaning is more specific than "Heterozygote".
This graph shows the total number of publications written about "Heterozygote" by people in this website by year, and whether "Heterozygote" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 9 | 9 |
| 1997 | 2 | 7 | 9 |
| 1998 | 3 | 10 | 13 |
| 1999 | 2 | 3 | 5 |
| 2000 | 0 | 14 | 14 |
| 2001 | 0 | 15 | 15 |
| 2002 | 1 | 10 | 11 |
| 2003 | 1 | 13 | 14 |
| 2004 | 1 | 13 | 14 |
| 2005 | 0 | 10 | 10 |
| 2006 | 1 | 12 | 13 |
| 2007 | 1 | 13 | 14 |
| 2008 | 3 | 7 | 10 |
| 2009 | 3 | 10 | 13 |
| 2010 | 2 | 11 | 13 |
| 2011 | 3 | 7 | 10 |
| 2012 | 0 | 12 | 12 |
| 2013 | 0 | 9 | 9 |
| 2014 | 2 | 17 | 19 |
| 2015 | 7 | 13 | 20 |
| 2016 | 4 | 13 | 17 |
| 2017 | 0 | 17 | 17 |
| 2018 | 0 | 18 | 18 |
| 2019 | 6 | 22 | 28 |
| 2020 | 1 | 23 | 24 |
| 2021 | 3 | 9 | 12 |
| 2022 | 1 | 11 | 12 |
| 2023 | 0 | 3 | 3 |
| 2024 | 2 | 6 | 8 |
| 2025 | 0 | 11 | 11 |
| 2026 | 1 | 8 | 9 |
To return to the timeline,
click here.
Below are the most recent publications written about "Heterozygote" by people in Profiles.
-
Baseline and placebo-related imaging, cerebrospinal fluid, plasma biomarker, and cognitive findings in unimpaired PSEN1 E280A mutation carriers and non-carriers in the Alzheimer's Prevention Initiative Autosomal Dominant Alzheimer's Disease Colombia Trial. EBioMedicine. 2026 Aug; 130:106390.
-
Neurodevelopmental Phenotypes and Brain Anomalies in Individuals With Heterozygous SEMA6A Variants. Clin Genet. 2026 Sep; 110(3):325-335.
-
Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial. Nat Med. 2026 Mar; 32(3):1052-1060.
-
Kv4.2V404M Mutation Induces Epileptiform Activity and Multiple Behavioral Abnormalities in Heterozygous Knock-in Mice. J Neurosci. 2026 02 11; 46(6).
-
Rare heterozygous missense variants in VSX2 are associated with retinal detachment. PLoS Genet. 2026 Feb; 22(2):e1012027.
-
Safety and efficacy of crenezumab in cognitively unimpaired carriers of the PSEN1Glu280Ala mutation at risk for autosomal-dominant Alzheimer's disease in Colombia (API ADAD Colombia Trial): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2026 Feb; 25(2):147-159.
-
Rare heterozygous de novo variants in RAPGEF2 are associated with a neurodevelopmental disorder. Genet Med. 2026 Apr; 28(4):101685.
-
Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial. JAMA. 2026 01 13; 335(2):129-139.
-
Germline HLA heterozygosity is associated with decreased lung cancer risk. HGG Adv. 2026 Apr 09; 7(2):100567.
-
BRCA1-, BRCA2-, and PALB2-related Fanconi anemia: Scope to expand disease phenotypic features and predict breast cancer risk in heterozygotes. Am J Hum Genet. 2025 12 04; 112(12):2902-2921.